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OBJECTIVES: To quantify medication adherence to
diuretic medication in heart failure (HF) patients and to
evaluate the relationship between adherence and health
care utilization. 
METHODS: Prospective, convenience sample; 
Adult patients with a current medical diagnosis of HF and
an active prescription for a diuretic from Wishard 
Memorial Hospital in Indianapolis, Indiana. Patients
were given a six-month supply of their diuretic in a bottle
capped with a microelectronic device (eDEM, Aprex Cor-
poration) to assess daily adherence (percentage of pre-
scribed doses taken) and scheduled adherence (percentage
of prescribed doses taken on time). Health care utiliza-
tion data were extracted from the Regenstrief Medical
Records System, which is Wishard’s clinical electronic
data repository. Data retrieved during the six-month
study period included numbers of hospitalizations and
emergency department (ED) visits classiﬁed as all reasons,
cardiac-related reasons, and heart failure-related reasons.
RESULTS: Patients (n = 42) were mostly single, middle-
aged patients with moderately severe HF. The mean daily
adherence and scheduled adherence were reported as
71.0% and 43.7%, respectively. All study patients were
hospitalized at least once during the study period and
most patients visited the ED. No relationship was found
between daily adherence and health care utilization.
However, signiﬁcant relationships were found between
scheduled adherence and both cardiac-related hospital
admissions (p = 0.0329) and cardiac-related ED visits 
(p = 0.0269). The risk of these clinical encounters
increased as scheduled adherence declined. 
CONCLUSION: These ﬁndings suggest that patients 
who are consistent with the administration of their loop
diuretic have fewer cardiac related hospitalizations and
ED visits. This result may be due to the known erratic
pharmacokinetic disposition of furosemide, the predom-
inate diuretic being used by patients in the study. Study
patients with low utilization may be taking their diuretic
at times that maximize the concentration-response rela-
tionship. This mechanism, and not the actual dose, may
contribute more to reduced utilization.
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EFFECT OF NON-ADHERENCE TO STATINS ON
ASSOCIATED COST EFFECTIVENESS
Heerey AM, Barry M
1National Centre for Pharmacoeconomics in Ireland, Dublin,
Ireland
OBJECTIVE: As lipid-lowering therapy is likely to be
long term and as many patients with hyperlipidemia 
are asymptomatic, adherence to HMG CoA Reductase
Inhibitors (statins) may be of relevance to the cost effec-
tiveness of these expensive agents. Therefore, rates of
statin usage in the Irish community setting were estab-
lished and effects on the incremental cost effectiveness
ratios (ICERs) of individual statin drugs in both primary
and secondary prevention of coronary heart disease
(CHD) calculated. 
METHODS: Non-adherence rates were established for
4,948 patients prescribed statins over an 18-month period
(Sept. 1999 to Feb. 2001) using a prescription-claims
database. A Markov model investigating the cost effec-
tiveness of statins, using Irish costs for medications and
acute myocardial infarction (AMI) treatment, Irish mor-
tality probabilities and outcomes for AMI and death from
the 4S trial for secondary prevention and the WOSCOPs
trial for primary prevention was adapted for these 
non-adherence rates. Changes in the discounted ICERs
per quality adjusted life year (QALY) were calculated.
RESULTS: Atorvastatin was the most cost-effective agent
in both primary and secondary prevention of CHD fol-
lowed by ﬂuvatstatin, simvastatin and pravastatin. ICERs
ranged from 1,172 to 3,900 Euro/QALY in secondary
prevention, increasing to 2,388 and 7,508 Euro/QALY
when non-adherence was factored. The effect in primary
prevention was even more apparent. Discounted
ICERs/QALY ranged from 17,668 Euro for atorvastatin
to 38,459 Euro for pravastatin. Effects of non-adherence
increased primary prevention ICERs to 24,663 and
57,494 Euro/QALY respectively. 
CONCLUSION: Non-adherence is rarely considered in
pharmacoeconomic evaluation. However, this study illus-
trates that non-compliance can have a signiﬁcant impact
on the cost effectiveness of all statins in the Irish setting.
This is likely to be the case for most expensive medica-
tions indicated over the long-term in all healthcare set-
tings. Therefore, the effects of non-compliance should be
considered before results from economic evaluation are
used to inﬂuence prescription choice.
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MORE MEDICATIONS AND DISEASE STATES
WERE RELATED TO AN INCREASE IN
MEDICATION ADHERENCE AMONG PATIENTS
AFTER A MYOCARDIAL INFARCTION
McBurney CR1, Erickson SR2, Kline-Rogers EM2, Smith DE2,
Eagle KA2
1University of Michigan and Pﬁzer Inc, Ann Arbor, MI, USA;
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OBJECTIVES: Nonadherence is a major reason for mor-
bidity and mortality. The purpose of this study was to
determine medication adherence of patients post myocar-
dial infarction (MI). 
METHODS: Patients admitted to the University of
Michigan Medical Center with diagnosis of MI were iden-
tiﬁed consecutively and prospectively from July 1999 to
July 2000. Clinical data were obtained retrospectively
from medical records including medications at discharge.
Patients were interviewed by telephone six months after
discharge. Follow-up data included a self-reported list of
medications and a four-item adherence questionnaire.
RESULTS: Complete information was obtained from 
216 patients. The mean age was 63.4 (+12.6) years and
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67.6% were male. Based upon the questionnaire, 36.1%
of patients reported nonadherence. Lower adherence rate
(49.1%) was obtained when comparing medications 
prescribed at discharge to medications documented at
follow-up. Based on the questionnaire, the more medica-
tion prescribed, the greater the adherence (p = 0.02).
Trend tests of adherence over increasing number of 
medications were positive in all medication classes 
(beta-blockers, ACE inhibitors, anticoagulants, and lipid
lowering drugs). Multivariate models show the similar
trend when adjusted for age and gender. Adherence 
also increased with more documented comorbidities (p =
0.01). When comparing medications prescribed to med-
ications at follow-up there were no signiﬁcant predictors
of adherence.
CONCLUSIONS: Nonadherence is frequent in patients
after an MI (36%). Utilizing a medication adherence
questionnaire to assess adherence is better than merely
comparing medication lists at two different points in time.
Better adherence to all four evidence-based therapies after
an MI is seen in patients prescribed more medications 
and with more disease states. Higher adherence may be
related to a recent major health event, more recent edu-
cation on treatment beneﬁts, and/or to a focus on reha-
bilitation. This study demonstrates the need for a larger,
broader study that includes health beliefs, psychosocial
assessment, and other patient factors that may inﬂuence
compliance.
ARTHRITIS & OSTEOPOROSIS—Clinical Outcomes
Presentation
PAO1
CARDIORENAL EFFECTS AND COSTS OF COX-
2 INHIBITORS IN A MANAGED CARE
ORGANIZATION
Yu-Isenberg KS1, Leslie RS1, Chang EY1,White TJ1, Bailey KL2
1Prescription Solutions, Costa Mesa, CA, USA; 2Pharmacia
Corporation, Peapack, NJ, USA
Arthritis—rheumatoid and osteoarthritis—is one of the
most prevalent chronic conditions affecting nearly 50%
of persons over the age of 65.
OBJECTIVES: The objective of this study was to
compare cardiorenal events and costs between two COX-
2 inhibitors—celecoxib and rofecoxib.
METHODS: This was a retrospective analysis of medical
and pharmacy claims. All patients newly started on a
COX-2 inhibitor during 7/1/99 to 6/30/00 were identiﬁed
and followed for 6 months before and after the initial
COX-2 prescription. Incident cardiorenal events were
attributable to a COX-2 if there was an ICD-9 diagnosis
code within 45 days after the last days supply of the 
prescription.
RESULTS: A total of 20,514 patients were newly pre-
scribed celecoxib (n = 12,487) or rofecoxib (n = 8,027).
Mean age was 65 (+/-15) and 68% were female. Primary
indication for COX-2 was pain (55%), followed by
osteoarthritis (23%), other arthritis (17%), and rheuma-
toid arthritis (6%). There were no signiﬁcant differences
in baseline cardiorenal history and medication use
(antiarthritic, antihypertensive, and GI-related) between
the two cohorts. Among the baseline hypertensive
patients, those on rofecoxib were 34% more likely to
experience an incident cardiorenal event than patients on
celecoxib, adjusting for age, gender, comorbidity, indica-
tion and dosage (OR = 1.34; p = 0.007). Results were
similar for the baseline non-hypertensive patients, with
those on rofecoxib reporting a higher risk of new car-
diorenal events (OR = 1.18; p = 0.0009). Although not
statistically signiﬁcant, patients on rofecoxib incurred
slightly higher total health care costs than those on cele-
coxib ($8,188 vs. $7,540; p = 0.0867).
CONCLUSION: The risk of cardiorenal events was 
signiﬁcantly higher in rofecoxib-treated patients than
celecoxib-treated patients. There were no statistically sig-
niﬁcant differences in total costs between the two COX-
2 inhibitors, although celecoxib-treated patients incurred
slightly lower total health care costs.
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TREATMENT PATTERNS OF CARE AND THE
RISK OF SUBSEQUENT FRACTURES AMONG
OSTEOPOROTIC WOMEN WITH INCIDENT
FRACTURES
Yu-Isenberg KS1,Ventura EP1, Chang EY1,White TJ1, Kemner
JE2, Ogostalick A3
1Prescription Solutions, Costa Mesa, CA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA; 3Eli Lilly and Company,
Anaheim, CA, USA
Osteoporosis affects 4–6 million women in the USA.
OBJECTIVES: The objective of this study was two-fold:
1) to evaluate treatment patterns of care associated 
with an incident fracture in postmenopausal women in a
managed care organization and 2) to estimate the inci-
dence of subsequent fractures by age.
METHODS: This was a retrospective analysis of medical
and pharmacy claims. Women aged 55 or older, with a
primary or secondary diagnosis of a new bone fracture
during calendar year 1999, and continuously enrolled in
the health plan were included in the sample. All claims
12-months before and 15-months after index fracture
date were evaluated for medication use and subsequent
fractures.
RESULTS: A total of 19,720 women had incident bone
fractures. Mean age was 78 years (+/-9.4). Of these
19,720 women, 90% had nonvertebral fractures, mainly
hip and wrist, and 10% had vertebral fractures. Overall
use of osteoporosis therapy, anytime before and after
index fracture, was 24% and 29%, respectively. Of the
women receiving therapy after fracture, 65% were 
prescribed estrogen, 28% bisphosphonates, 17% nasal
calcitonin, 14% combination therapy, primarily a bis-
phosphonate plus estrogen, and 5% raloxifene. Only
25% of treated women remained on therapy for at least
